Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study to Evaluate Safety and Persistence of Ex Vivo Expanded Universal Donor NK Cells in Combination with IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients with Locally Advanced/metastatic Colorectal Cancer, Gastric/esophageal Cancer, and Relapsed/refractory Hematologic Malignancies

Next Previous
Trial Profile

A Phase Ib Study to Evaluate Safety and Persistence of Ex Vivo Expanded Universal Donor NK Cells in Combination with IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients with Locally Advanced/metastatic Colorectal Cancer, Gastric/esophageal Cancer, and Relapsed/refractory Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary) ; Vactosertib (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia; Adenocarcinoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Gastric cancer; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Oesophageal cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 10 May 2024 Status changed from suspended to recruiting.
  • 29 Mar 2024 Planned End Date changed from 1 Dec 2024 to 1 Jun 2026.
  • 29 Mar 2024 Planned primary completion date changed from 1 Jun 2024 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top